Articles tagged "Adverse effects"

2022 American Transplant Congress
Incidence of Dapsone-Induced Methemoglobinemia in Solid Organ Transplant Recipients
D. Quan¹, R. Gordon¹, J. Lee¹, D. Khoshabafard², A. Han¹
¹Pharmacy, UCSF Medical Center, San Francisco, CA, ²Clinical Phamacy, UCSF School of Pharmacy, San Francisco, CA
*Purpose: The purpose of this study was to determine the incidence of dapsone-induced methemoglobinemia in solid organ transplant recipients.*Methods: This was a single-center retrospective cohort…
2022 American Transplant Congress
Physiological Age by Artificial Intelligence-Enhanced Electrograms as a Novel Biomarker of Mortality in Kidney Transplant Candidates
E. Lorenz, I. Zaniletti, B. Johnson, T. Petterson, W. Kremers, C. Schinstock, H. Amer, A. Cheville, N. LeBrasseur, A. Baez-Suarez, Z. Attia, F. Lopez-Jimenez, P. Friedman, C. Kennedy, A. Rule
Mayo Clinic, Rochester, MN
*Purpose: Assessing mortality risk prior to kidney transplantation is challenging. Age-Gap, which is the difference between physiological age determined by artificial intelligence-enhanced electrocardiograms (ECG) and…
2022 American Transplant Congress
Transplant Graft TMA Injury Post COVID-19 Vaccination
O. Sogbein, A. Rizvi, M. Mujtaba, S. Hussain
Internal Medicine, Division of Nephrology, University of Texas Medical Branch, Galveston, TX
*Purpose: Vaccination against SARS-CoV-2 is essential. Complicating this effort are reports of a suboptimal response to the SARS-CoV-2 spike protein in patients on immunosuppressive medications…
2022 American Transplant Congress
Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study
R. M. La Hoz¹, D. Florescu², D. Kumar³, F. Saliba⁴, J. Gu⁵, A. Sundberg⁵
¹Univ. Texas Southwestern Medical Center, Dallas, TX, ²Univ. Nebraska Medical Center, Omaha, NE, ³Univ. Health Network, Toronto, ON, Canada, ⁴Univ. Paris Saclay, Paris, France, ⁵Takeda Development Center Americas, Inc., Lexington, MA
*Purpose: In a Phase 3 study of MBV vs IAT (val/ganciclovir, foscarnet, or cidofovir) for refractory CMV infection (with/without resistance; R/R) in hematopoietic cell transplant…
2022 American Transplant Congress
Telemedical Surveillance and Optimized Treatment of Blood Pressure in Kidney Transplant Recipients
W. Düttmann¹, M. G. Naik¹, B. Zukunft¹, B. Osmanodja¹, G. Eleftheriadis¹, S. Ronicke², M. Choi¹, F. Bachmann¹, F. Halleck¹, K. Budde¹
¹Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Patients with chronic kidney disease suffer often from cardiovascular diseases, especially high blood pressure and its complications such as stroke and heart attack. After…
2022 American Transplant Congress
An Interim Report on a Prospective Randomized Trial of Extended-Release Tacrolimus in Liver Transplantation with Anti-Thymocyte Induction in a Steroid Free Protocol
R. A. Helmick, S. Naik, C. Eymard, J. Eason, J. Vanatta
James D. Eason Transplant Institute at Methodist University Hospital and University of Tennessee Health Science Center, Memphis, TN
*Purpose: Our study hypothesis was that once daily dosing of extended-release tacrolimus (ERT) would be a safe and effective immunosuppression (IS) with the potential to…
2022 American Transplant Congress
Impact Of Nirmatrelvir-Ritonavir On Tacrolimus Concentrations
S. Fredrick¹, B. Wise², L. Bowman², D. DeWolfe¹, J. Taylor¹, J. Melaragno¹
¹University of Rochester Medical Center, Rochester, NY, ²Tampa General Hospital, Tampa, FL
*Purpose: Ritonavir (RTV), a component of the oral antiviral agent nirmatrelvir-RTV (Paxlovid) for COVID-19 infection, increases tacrolimus concentrations through strong competitive inhibition of gastrointestinal and…
2022 American Transplant Congress
Clinical Outcomes with IR-tac to LCP-tac Conversion in a Kidney Transplant Population
F. Bartlett¹, J. Newman¹, T. Sprague¹, S. Patel¹, N. Rao², E. Andrade², V. Rohan², M. Casey², D. Dubay¹, D. Taber¹
¹Pharmacy, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is approved for conversion from IR-Tac in kidney transplant patients with a conversion rate of 70-80%. Studies have demonstrated similar efficacy and safety…
2022 American Transplant Congress
Incidence and Risk Factors Associated with the Development of Hypoglycemia After Combined Pancreas-Kidney Transplantation
S. Kapoor¹, S. Jain², S. Stefan³, Y. Azzi³, M. Ajaimy³, P. Loarte-Campos³, C. Pynadath³, H. C. Yaffe³, M. Le³, J. Rocca³, S. Greenstein³, M. Kinkhabwala³, J. Graham³, E. Akalin⁴, L. Liriano-Ward³
¹Montefiore Medical Center, New York, NY, ²Montefiore Medical Center, Scarsdale, NY, ³Montefiore Medical Center, Bronx, NY, ⁴Albert Einstein College of Medicine, Montefiore Medical Ctr, Bronx, NY
*Purpose: To review the incidence of hypoglycemia after pancreas transplantation in recipients with type 1 and 2 diabetes mellitus and the risk factors associated with…
2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
E. Foster¹, A. Iaria¹, J. Negrelli², M. Fine², M. Yu², M. Liebo²
¹University of Illinois at Chicago, Chicago, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…